Cytomegalovirus (CMV) Vaccines Market – Global Analysis & Forecast, 2019 – 2030
Report ID : 219 | Region : Global
Cytomegalovirus (CMV) also known as HCMV, or Human Herpes virus 5 (HHV-5) is the virus most commonly transmitted to a developing fetus. It is a common virus that infects people of all ages. According to CDC, over half of adults by age 40 have been infected with CMV. Most people infected with CMV show no signs or symptoms. Whereas when a baby is born with cytomegalovirus (CMV) infection, it is called as congenital CMV. Each year, approximately 5,000 infants in U.S. may develop permanent problems due to CMV, some of the severe problems, includes deafness, blindness, and mental retardation. Furthermore, global prevalence of congenital cytomegalovirus is said to be 0.3 – 2.0%. The Institute of Medicine (IOM) of the National Academy of Sciences, has designated CMV as a “highest priority” category for vaccine development, citing the years of life and disability that could be saved.
Increasing incidences & prevalence of CMV, and rising investments towards the development of Cytomegalovirus (CMV) vaccines by numerous, major & small companies, coupled with large number of pipeline products can be attributed to the growing demand for global cytomegalovirus (CMV) vaccines market in the coming years.
Key companies are accelerating robust product development pipeline. Merck’s, AlphaVax, Inc., and Moderna, Inc. are some companies working on CMV immunizations.
To gather deep-rooted insights with respect to market dynamics, competitive landscape and to unlock the market potential of Cytomegalovirus (CMV) vaccines, subscribe to the report by clicking and filling up the ‘Pre-book’ section.